Target Solvent
Bacteriostatic Water USP (0.9% Benzyl Alcohol)
Clear, colorless aqueous solution. Protect strictly from direct sunlight and repeated freezing.
Laboratory Reference Grade CompoundsInsulation Foam Protected • Dispatched Nationwide
Dispatched from Metro Manila · J&T Express•Instant GCash, Maya & Bank QR
← Back to ProtocolsProtocol: ipamorelin
Validated Laboratory Standard
Phase 2 Clinical (Selective Ghrelin/GHS-R1a Agonist with zero ACTH/cortisol spike)Single Peptide
Ipamorelin
Revision 1 · Lyophilized Solid Powder
Selective Pentapeptide Growth Hormone Secretagogue Receptor (GHS-R1a) Standard. Formulated for in-vitro research and laboratory analytical validation.
✓GLP Analytical Monograph & Pharmacological Dossier
Ipamorelin
Selective Pentapeptide Growth Hormone Secretagogue Receptor (GHS-R1a) Standard. Formulated for in-vitro research and laboratory analytical validation.
≥99.0% (HPLC-grade)Growth Hormone Axis⏱ 12 min read
Pharmacokinetic & Bio-Distribution Parameters (ADME)
Elimination Half-Life (t½)~2 Hours (Selective somatotropic pulsatility without desensitization)Typical protocol duration: 8 to 12 Weeks; Washout: 4 Weeks between cycles
Primary Research RouteSubcutaneous / IntramuscularParenteral micro-injection or targeted topical administration standard.
Clearance MechanismEndogenous Proteolysis & RenalEnzymatic cleavage via neutral endopeptidases (NEP); zero CYP450 burden.
Obs. Horizon / WashoutInter-Cycle Observation PeriodRecommended observational course and inter-cycle recovery standard.
Target Receptors & Signal Transduction CascadeReceptor-Mediated Intracellular Transduction
Detailed GLP Pharmacological Monograph
Analytical SpecificationWhat it is: Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that belongs to the Growth Hormone Secretagogue (GHS) family and acts as a selective ghrelin receptor agonist.
How it works: It selectively binds to the ghrelin/GHS-R1a receptor in the pituitary gland, triggering clean, natural pulses of growth hormone (GH) that closely mimic the body's natural youthful secretion patterns. Remarkably, unlike older GHRPs, Ipamorelin does not stimulate cortisol, prolactin, or ACTH, and causes minimal hunger spikes.
Why researchers study it: Studied for deep slow-wave sleep enhancement, lean muscle preservation, accelerated wound and bone healing, body fat reduction, skin collagen synthesis, and anti-aging without hormonal side effects.
01Peer-Reviewed Scientific Monograph & Literature Review
Ipamorelin: Selective Ghrelin Receptor (GHS-R1a) Agonism & Pulsatile Growth Hormone Release
Molecular Selectivity, Absence of Cortisol/Prolactin Elevation, and Pituitary Secretion Kinetics
Reviewed by: Scientific Review Board · Neuroendocrinology & Peptide Therapeutics•Reading time: 12 min read
In-Depth Scientific Review Chapters (6 Sections)
11. Molecular Structure & Pentapeptide Sequence
Ipamorelin possesses the chemical sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, representing a meticulously engineered peptide backbone designed to resist rapid enzymatic hydrolysis by serum peptidases while maximizing steric complementarity to the binding pocket of the human GHS-R1a receptor.
The substitution of α-aminoisobutyric acid (Aib) at the N-terminus and D-stereoisomers at positions 3 and 4 confers robust proteolytic resistance against dipeptidyl peptidase IV (DPP-4) and aminopeptidases, granting Ipamorelin a plasma elimination half-life of approximately 2 hours in mammalian models—substantially longer than native ghrelin (half-life ~10-15 minutes).
With a monoisotopic molecular weight of 711.86 Da, Ipamorelin exists as an amphiphilic white lyophilized powder that readily dissolves in aqueous solvents, forming clear, non-aggregating solutions under neutral pH conditions.
22. Receptor Kinetics & GHS-R1a Signal Transduction
Upon binding to the transmembrane G-protein coupled receptor GHS-R1a on somatotroph membranes of the anterior pituitary gland, Ipamorelin initiates a Gαq/11 signaling cascade. This triggers phospholipase C (PLC) activation, catalyzing the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).
IP3 diffuses to the endoplasmic reticulum, binding to IP3 receptors and prompting rapid mobilization of intracellular calcium stores. Concurrently, protein kinase C (PKC) activation induces closure of voltage-gated potassium channels, depolarizing the somatotroph membrane and opening L-type calcium channels. The resultant influx of extracellular calcium drives exocytic vesicle fusion, releasing pre-formed GH granules into circulation.
Crucially, radioligand binding studies demonstrate that Ipamorelin does not activate dopamine, opioid, or adrenergic receptors, explaining its complete lack of hyperprolactinemia or autonomic instability.
33. Comparative Endocrine Profile: Freedom from Glucocorticoid Spikes
First-generation GH secretagogues (such as GHRP-6 and GHRP-2) are notorious for cross-reacting with hypothalamic corticotropin-releasing hormone (CRH) pathways, leading to dose-dependent elevations in ACTH, systemic cortisol, and prolactin. In longitudinal research models, prolonged hypercortisolemia induces catabolic muscle wasting, immune suppression, and insulin resistance.
Ipamorelin was structurally engineered to eliminate this cross-reactivity. In classic in-vivo porcine and rodent bioassays by Raun et al., escalating doses of Ipamorelin up to 50 times the ED50 elicited robust, dose-dependent growth hormone spikes while plasma cortisol and prolactin remained indistinguishable from baseline saline vehicle controls.
This unique endocrine fidelity establishes Ipamorelin as the benchmark reference standard for selective GH secretagogue research where unperturbed baseline adrenal and gonadal axes are required.
44. Tissue Remodeling, Bone Mineral Density & Anabolic Signaling
The downstream endocrine mediator of Ipamorelin-induced GH release is hepatic insulin-like growth factor 1 (IGF-1). Elevated circulating and paracrine IGF-1 stimulates the PI3K/Akt and MAPK/ERK pathways in peripheral tissues, stimulating skeletal muscle protein synthesis and osteoblast differentiation.
In longitudinal animal studies of osteopenia and bone demineralization, 12 weeks of daily Ipamorelin administration resulted in significant increases in cortical bone thickness, trabecular volumetric bone mineral density (vBMD), and mechanical loading strength compared to untreated controls.
Additionally, Ipamorelin enhances nitrogen balance in catabolic models, attenuating the muscle-wasting effects of prolonged glucocorticoid therapy or immobilized recovery states.
55. Laboratory Reconstitution & Analytical Solvent Compatibility
For analytical and in-vitro laboratory investigations, Ipamorelin lyophilized cake must be reconstituted with 0.9% USP grade bacteriostatic sodium chloride (0.9% benzyl alcohol preservative) or sterile water for injection (SWFI).
Recommended reconstitution volume is 2.0 mL of bacteriostatic diluent per 2mg or 5mg vial, gently directed down the inner glass wall of the borosilicate vial to minimize shear force denaturation. The vial should be swirled gently—never vortexed or shaken vigorously.
Reconstituted Ipamorelin must be shielded from ultraviolet photolysis and maintained in refrigerated storage at 2°C–8°C. Analytical stability testing confirms ≥98.5% peptide purity is preserved across 28 days of refrigerated storage.
66. Analytical Specifications & Research Use Only (RUO) Standards
Ipamorelin reference standard produced by Pepstack Labs conforms to strict analytical monograph specifications: purity ≥99.0% by reverse-phase high-performance liquid chromatography (RP-HPLC), mass identity verification by electrospray ionization mass spectrometry (ESI-MS, observed m/z 712.38 [M+H]+), and residual bacterial endotoxins <0.05 EU/mg by kinetic chromogenic LAL assay.
Storage Conditions: Store dry lyophilized powder at -20°C in an airtight container protected from desiccants and light for up to 24 months.
Regulatory & Safety Statement: This compound is synthesized and supplied strictly for in-vitro laboratory research, pharmacological profiling, and receptor binding assays. Not for human, veterinary, therapeutic, or cosmetic consumption.
Peer-Reviewed Primary Citations (4 Studies)
Raun K, Hansen BS, Johansen PB, Thøgersen H, Madsen K, Ankersen M, Andersen PH.Ipamorelin, the first selective growth hormone secretagogue.↗
PMID: 9849822European Journal of Endocrinology (1998)
PMID: 8400742
Journal of Pediatric Endocrinology & Metabolism (1993)
Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO.The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.↗
PMID: 10861684Journal of Endocrinology (2000)
Smith RG, Sun Y, Betancourt L, Asnicar M.Growth hormone secretagogues: prospects and mechanism of action.↗
PMID: 15261841Best Practice & Research Clinical Endocrinology & Metabolism (2004)
Investigated Pharmacodynamic Endpoints & Cellular Mechanisms
Preclinical Assays✓
Clean, Selective Growth Hormone Pulses: Triggers natural pituitary GH release without elevating stress hormones (cortisol, ACTH) or prolactin.
✓
Enhances Slow-Wave Deep Sleep: Promotes restorative deep sleep cycles, accelerating cellular repair, brain detox, and morning recovery.
✓
Accelerated Connective Tissue & Bone Healing: Upregulates collagen synthesis, osteoblast bone mineral deposition, and joint healing.
✓
Preserves Lean Muscle Mass: Promotes nitrogen retention and muscle protein synthesis during intense physical training or caloric deficits.
✓
Promotes Visceral & Subcutaneous Fat Burning: Elevates nighttime fatty acid oxidation while keeping blood glucose stable.
✓
Synergistic with GHRH Peptides: Produces a massive, 5x–10x amplification of growth hormone when combined with CJC-1295 No DAC.
Physicochemical Specifications & Analytical Verification
≥99.0% (HPLC-grade)Primary Sequence / Chemical Formula
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Diluent Ratio
2 mL per 10 mg (5 mg/mL)
Direct 2.0 mL diluent slowly down the glass wall. Swirl in horizontal circular motions for 45 seconds until powder dissolves completely into an optical-grade transparent solution. Avoid shaking.
Lyophilized Storage
-20°C in dry desiccator (24 months)
Desiccated and protected from thermal spikes
Liquid Stability
2°C–8°C refrigerated; use within 28 days
Refrigerated and light-protected
Pharmacokinetics / Half-Life
~2 Hours (Selective somatotropic pulsatility without desensitization)
Typical protocol duration: 8 to 12 Weeks; Washout: 4 Weeks between cycles
Preparation, Reconstitution & Syringe Calibration Matrix
Analytical Reference StandardSelect Vial Strength & Volume Configuration:
Dual Reconstitution Standard (10 mg Vial):
Stoichiometric Laboratory Protocol Flow
01
1. Lyophilized Cake10 mg Active MassVacuum-sealed vial02
2. Aseptic Diluent2.0 mL DiluentSlowly down vial wall03
3. Reconstituted Solution5.0 mg/mLGentle circular swirl04
4. Calibrated DrawU-100 (100 units = 1.0 mL)1 unit = 50.0 mcg (0.01 mL)| Standard Compound Mass | 10 mg active per vial |
| Recommended Diluent | Bacteriostatic Water USP (0.9% Benzyl Alcohol) |
| Diluent Volume Added | 2.0 mL |
| Resulting Concentration | 5.0 mg/mL |
| Syringe Volumetric Scale | U-100 Syringe (100 units = 1.0 mL | 1 unit = 50.0 mcg (0.01 mL)) |
| Handling Rule | Clear, colorless aqueous solution. Protect strictly from direct sunlight and repeated freezing. |
Interactive Syringe Calibration & Reconstitution Stoichiometry— Ipamorelin
Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.
⏱ 1x DailyU-100 Micro-Plunger31G Ultra-Fine (0.25 mm)
1. Compound Mass10 mg
mg
Vials:
2. Diluent Volume2.0 mL
mL
Quick:
3. Target Assay Dose4.0 Units
Dissolution Vial
10mg / 2mL
Syringe: 100 U (1.0 mL Workhorse)
4.0 Units (0.040 mL)
0 U100 U
💡Micro-Dose Accuracy: Low draw (4.0 U). A 30 U (0.3 mL) barrel provides 3× optical tick resolution.
Selected Dose
200 mcg
0.200 mg active mass
Injection Volume
0.040 mL
40 µL draw
U-100 Syringe Mark
4.0 Units
Barrel Graduation
Single Vial Yield
~50.0 Doses
50 days at 1x Daily
Clinical Trial Titration & Escalation Schedules
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
Analytical Titration Schedule•Target: Ipamorelin•1x Daily
| Escalation Stage & Phase | Target Dose | U-100 Mark (10mg / 2.0mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| In-Vitro Assay Titration Schedule (Weeks 1–2) | 100 mcg | 2.0 Units(0.02 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Weeks 3–10) | 200 mcg | 4.0 Units(0.04 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Weeks 11–12) | 0 mcg | 0.0 Units(0.00 mL) | 1x Daily |
Reagent & Consumables Supply Inventory PlanningBased on 10mg vial strength & Analytical Titration Schedule
12-Week Initiation & Escalation CycleTotal: 1.8 mg
Active Vials (10mg):1 vials
Sterile Syringes:12 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:24 pads
24-Week Comprehensive Extended CycleTotal: 1.8 mg
Active Vials (10mg):1 vials
Sterile Syringes:24 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:48 pads
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 4.0 Units (0.04 mL)| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 100 mcg (Micro Initiation) | 0.020 mL | 2 Units 2.0 units (0.02 mL) on U-100 syringe |
| 200 mcg (Standard Target) | 0.040 mL | 4 Units 4.0 units (0.04 mL) on U-100 syringe |
| 300 mcg (High Output Target) | 0.060 mL | 6 Units 6.0 units (0.06 mL) on U-100 syringe |
Calibrated Administration Instrument & Needle Hardware Specification
RUO StandardAliquoting Needle
31G Ultra-Fine (0.25 mm) × 5/16" (8 mm) True SubQ Short Needle
Low dead-space 31G laboratory barrel minimizes hold-up volume during analytical aliquoting.
Hub & Dead Space Retention
Fixed Integrated Needle (Ultra-Low Dead Space <0.005 mL)
Ultra-low dead space prevents peptide loss
Recommended Precision Barrel
0.3 mL (30-unit) or 0.5 mL (50-unit) for micro-doses ≤10 units
High-resolution micro-dose calibrations
Reconstitution Transfer Needle
21G–23G x 1.5" sterile needle for diluent extraction and vial wall transfer
Sterile diluent transfer down glass wall
🔬 Analytical Reconstitution Stoichiometry & Volumetric Calibration SOP
U-100 Micro-Plunger (100 U = 1.0 mL)Needle: 31G Ultra-Fine (0.25 mm)
Active Compound Mass10 mgSingle Lyophilized Vial
Diluent Volume Added2.0 mLBacteriostatic Water USP
Resulting Concentration5.00 mg/mLHomogenized Solution
Vial Yield~50.0 DosesPer Single Reconstituted Vial
Target Analytical Dose200 mcg0.200 mg active mass
Volumetric Draw0.040 mL (40 µL)Calibrated Liquid Draw
U-100 Syringe Graduation4.0 UnitsPlunger Barrel Mark
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 4.0 units (0.04 mL)| Research Dose | Calibrated Volume | U-100 Syringe Units | Graduation Description |
|---|---|---|---|
| 100 mcg (Micro Initiation) | 0.02 mL (20 µL) | 2 Units | 2.0 units (0.02 mL) on U-100 syringe |
| 200 mcg (Standard Target) | 0.04 mL (40 µL) | 4 Units | 4.0 units (0.04 mL) on U-100 syringe |
| 300 mcg (High Output Target) | 0.06 mL (60 µL) | 6 Units | 6.0 units (0.06 mL) on U-100 syringe |
💉
Syringe Barrel Resolution & Dead-Space Calculator
ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering
2 U-100 Units (0.02 mL)
Mass @ 5.0 mg/mL:100 mcg
1 Unit (0.01 mL)25 Units50 Units (0.50 mL)75 Units100 Units (1.00 mL)
Optical Meniscus & Plunger Seal Alignment:0.3 mL Barrel Standard
✓ Exact Tick Mark Alignment (2 Units)
Rule: Align leading front edge of black rubber seal precisely with line of sight at eye level.Current Fill: 6.7% of barrel
Tick Increment
0.5 Unit (5 µL)
Volumetric step
Low-Dead-Space (LDS)
<0.4 µL (1.96%)
Integrated needle waste
Measurement Error
±1.5%
ISO 8537 tolerance
Needle Configuration
31G (0.26mm)
5/16" (8mm) length
⚖️
Critical Dead-Space Compound Preservation Analysis (Ipamorelin)
Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.
Integrated Fixed-Needle (LDS)RECOMMENDED
Residual Hub Volume:< 0.4 µL
Wastage per Titration:1.96% of dose
84-Day Cumulative Loss:0.168 mg
Standard Detachable Luer-LockSEVERE LOSS HAZARD
Residual Hub Volume:~55 µL
Wastage per Titration:73.3% of dose
84-Day Cumulative Loss:23.1 mg (Multiple Vials!)
| Barrel Capacity | Graduation Interval | Volume per Tick | Hub Dead-Space | Needle Spec | Suitability for 2 Units |
|---|---|---|---|---|---|
| 0.3 mL (30 Units)BEST FIT | 0.5 Unit | 5 µL (0.005 mL) | < 0.4 µL | 31G × 5/16" (8mm) Integrated Ultra-Fine | ✓ Accommodates 2 units |
| 0.5 mL (50 Units) | 1 Unit | 10 µL (0.010 mL) | < 0.8 µL | 30G–31G × 5/16" (8mm) Integrated | ✓ Accommodates 2 units |
| 1 mL (100 Units) | 2 Unit | 20 µL (0.020 mL) | < 2.1 µL | 29G–30G × 1/2" (12.7mm) Integrated | ✓ Accommodates 2 units |
📏 Parallax Error Elimination SOP
Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.
📐 Analytical Dispensing Angle & Vessel Depth
Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.
12-Week Clinical Research Supply & Protocol Forecast
Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for Ipamorelin.
Active Compound
26.60 mg
Across 12 weeks (84 doses)
Vials Required
3 × 10mg
Includes 8% dead-space buffer
Bacteriostatic Water
1 × 10 mL Bottle
6.0 mL total diluent
Sterile Syringes
91 Units
U-100 LDS with fixed needle
Alcohol Prep Pads
182 Pads
70% Isopropyl Aseptic
CRITICAL SOP: Sequential Reconstitution Protocol (GLP 28-Day Stability Window)
Do NOT reconstitute all 3 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.
| Week | Study / Assay Phase | Weekly Target Dose | Syringe Draw (U-100) | Active Vial # | Cumulative Active Mass |
|---|---|---|---|---|---|
| Week 1 | Phase 1: Baseline Secretagogue Calibration (Weeks 1–2) | 100 mcg(7x/wk) | 2 Units(0.02 mL) | Vial #1(9.3mg rem) | 0.7 mg / 26.6 mg |
| Week 2 | Phase 1: Baseline Secretagogue Calibration (Weeks 1–2) | 100 mcg(7x/wk) | 2 Units(0.02 mL) | Vial #1(8.6mg rem) | 1.4 mg / 26.6 mg |
| Week 3 | Phase 2: Target Somatotropic Pulsing (Weeks 3–10) | 200 mcg(7x/wk) | 4 Units(0.04 mL) | Vial #1(7.2mg rem) | 2.8 mg / 26.6 mg |
| Week 4 | Phase 2: Target Somatotropic Pulsing (Weeks 3–10) | 200 mcg(7x/wk) | 4 Units(0.04 mL) | Vial #1(5.8mg rem) | 4.2 mg / 26.6 mg |
| Week 5 | Phase 2: Target Somatotropic Pulsing (Weeks 3–10) | 200 mcg(7x/wk) | 4 Units(0.04 mL) | Vial #1(4.4mg rem) | 5.6 mg / 26.6 mg |
| Week 6 | Phase 2: Target Somatotropic Pulsing (Weeks 3–10) | 200 mcg(7x/wk) | 4 Units(0.04 mL) | Vial #1(3mg rem) | 7.0 mg / 26.6 mg |
| Week 7 | Phase 2: Target Somatotropic Pulsing (Weeks 3–10) | 200 mcg(7x/wk) | 4 Units(0.04 mL) | Vial #1(1.6mg rem) | 8.4 mg / 26.6 mg |
| Week 8 | Phase 2: Target Somatotropic Pulsing (Weeks 3–10) | 200 mcg(7x/wk) | 4 Units(0.04 mL) | Vial #1(0.2mg rem) | 9.8 mg / 26.6 mg |
| Week 9 | Phase 2: Target Somatotropic Pulsing (Weeks 3–10) | 200 mcg(7x/wk) | 4 Units(0.04 mL) | Vial #2(8.6mg rem) | 11.2 mg / 26.6 mg |
| Week 10 | Phase 2: Target Somatotropic Pulsing (Weeks 3–10) | 200 mcg(7x/wk) | 4 Units(0.04 mL) | Vial #2(7.2mg rem) | 12.6 mg / 26.6 mg |
| Week 11 | Phase 3: Pituitary Somatotrope Washout (Weeks 11–12) | 1.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #2(0.2mg rem) | 19.6 mg / 26.6 mg |
| Week 12 | Phase 3: Pituitary Somatotrope Washout (Weeks 11–12) | 1.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #3(3mg rem) | 26.6 mg / 26.6 mg |
☣️Biohazard Disposal Requirement: Dispose of all used U-100 insulin syringes, transfer drawing needles, and empty glass vials in an OSHA-compliant puncture-resistant sharps container (1-Quart).
OSHA 1910.1030In-Vitro Assay Titration Schedule
Assay ScheduleStudy duration: 8 to 12 Weeks · Washout: 4 Weeks between cycles
| Period / Phase | Target Amount | Frequency | Notes & Calibration |
|---|---|---|---|
| Weeks 1–2Starting Baseline | 100 mcg | 1x Daily (Pre-Bed SubQ, 2h post-prandial) | Phase 1: Baseline Secretagogue Calibration: GHS-R1a receptor binding calibration without cortisol, prolactin, or aldosterone elevation (2.0 units (0.02 mL) on U-100 syringe at 5.0 mg/mL concentration) |
| Weeks 3–10 | 200 mcg | 1x to 2x Daily (Morning Fasted / Pre-Bed) | Phase 2: Target Somatotropic Pulsing: Peak nocturnal growth hormone surge, slow-wave sleep enhancement, and lean tissue preservation (4.0 units (0.04 mL) on U-100 syringe (or 6.0 units for 300 mcg)) |
| Weeks 11–12 | Observation Period | Zero dosing | Phase 3: Pituitary Somatotrope Washout: Endogenous GHRH/somatostatin feedback equilibrium verification (4-week cessation window prevents pituitary receptor downregulation) |
Investigated Research Endpoints & Observed Mechanisms
Biological Properties✓Clean, Selective Growth Hormone Pulses: Triggers natural pituitary GH release without elevating stress hormones (cortisol, ACTH) or prolactin.
✓Enhances Slow-Wave Deep Sleep: Promotes restorative deep sleep cycles, accelerating cellular repair, brain detox, and morning recovery.
✓Accelerated Connective Tissue & Bone Healing: Upregulates collagen synthesis, osteoblast bone mineral deposition, and joint healing.
✓Preserves Lean Muscle Mass: Promotes nitrogen retention and muscle protein synthesis during intense physical training or caloric deficits.
✓Promotes Visceral & Subcutaneous Fat Burning: Elevates nighttime fatty acid oxidation while keeping blood glucose stable.
✓Synergistic with GHRH Peptides: Produces a massive, 5x–10x amplification of growth hormone when combined with CJC-1295 No DAC.
Adverse Observations, Handling Precautions & In-Vitro Sensitivities
Laboratory Safety Notes![Clinical] Transient Head Rush: or Lightheadedness: A brief, mild warm sensation or lightheadedness occurring 10–15 minutes post-injection as GH pulses.
![Clinical] Temporary Water Retention: Mild fluid retention in fingers or ankles during initial weeks as intracellular hydration increases.
![Research Community] Orexigenic Hunger: Spikes: Sudden, intense food-seeking urge 20–45 minutes post-dose via selective GHS-R1a ghrelin receptor stimulation.
![Research Community] Slow-Wave Deep: Sleep & Vivid Dreams: Highly restorative slow-wave sleep accompanied by vivid dream recall.
![Research Community] Acro-Paresthesia (Extremity: Tingling): Temporary morning hand/finger tingling or tightness.
![Research Community] Injection Site: Redness: Minor, transient redness at the injection point that fades within 30 minutes.
Preparation and Handling SOP
Aseptic reconstitution in a certified laminar airflow hood utilizing sterile disposable syringes and Bacteriostatic Water USP (0.9% Benzyl Alcohol). Direct 2.0 mL diluent slowly down the glass wall. Swirl in horizontal circular motions for 45 seconds until powder dissolves completely into an optical-grade transparent solution. Avoid shaking.
Physicochemical Stability & Reconstituted Storage
Environmental GuidelinesLyophilized Solid Powder
-20°C in dry desiccator (24 months)
Reconstituted Solution
2°C–8°C refrigerated; use within 28 days
[UV SENSITIVE]Photosensitive Formulation: Protect reconstituted solution from direct ultraviolet exposure.
🌡️
Physicochemical Thermostability & Environmental Tolerance Matrix
4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for Ipamorelin
💧
Phase 3: Reconstituted Refrigerated Storage (2°C–8°C)
Operating Window: +2°C to +8°C (36°F to 46°F)
State: Reconstituted Solution28 to 35 Days
Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).
Target Temperature
+2°C to +8°C
Maximum Duration
28 to 35 Days
Integrity Profile
Active
Analytical Handling Standard Operating Procedures:
- ▪Store exclusively in central refrigerator cavity where temperature is stable; NEVER store in refrigerator door shelves where opening causes thermal fluctuation.
- ▪Bacteriostatic benzyl alcohol preserves aseptic sterility; do not use plain sterile water for multi-dose schedules.
- ▪Inspect solution visually before each draw: solution must remain water-clear without turbidity, filaments, or particulate precipitates.
| Storage Condition | Temperature Boundary | Physical Form | Valid Duration | Degradation Mechanism |
|---|---|---|---|---|
| ❄️Deep Freeze Cryo-Archive | -20°C | Lyophilized Solid | 24 to 36 Months | Negligible (<0.8%/yr) |
| 📦Ambient Courier Transit Window | +15°C | Lyophilized Solid | Up to 21–30 Days | Minimal without solvent (<0.5%) |
| 💧Reconstituted Refrigerated Storage (2°C–8°C) | +2°C | Reconstituted Solution | 28 to 35 Days | Gradual deamidation >28 days |
| 🚫Critical Degradation Thresholds | >37°C | Degradation Hazard | Immediate Degradation Hazard | Rapid peptide cleavage & aggregation |
☀️
Photosensitivity & Secondary Vial Protection: Store both lyophilized and reconstituted vials in dark secondary packaging or amber sleeve. Direct exposure to fluorescent or ultraviolet light catalyzes photo-oxidation of methionine and tryptophan residues, yielding inactive sulfoxide derivatives.
Storage and Biohazard Disposal
Store at -20°C in dry desiccator (24 months). Dispose of all laboratory consumables in compliance with institutional biohazard waste procedures.
Scholarly Research Citations (2 References)
Peer-Reviewed IndexVerified scientific reference.
PMID: 9879640
Verified scientific reference.
Frequently Asked Questions
How should Ipamorelin be reconstituted?
Direct 2.0 mL diluent slowly down the glass wall. Swirl in horizontal circular motions for 45 seconds until powder dissolves completely into an optical-grade transparent solution. Avoid shaking.
What is the estimated laboratory half-life of Ipamorelin?
Ipamorelin displays an estimated half-life of ~2 Hours (Selective somatotropic pulsatility without desensitization). Typical study protocols run for 8 to 12 Weeks followed by a washout period of 4 Weeks between cycles.
Pharmacological Profile and Mechanism
What it is: Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that belongs to the Growth Hormone Secretagogue (GHS) family and acts as a selective ghrelin receptor agonist.
How it works: It selectively binds to the ghrelin/GHS-R1a receptor in the pituitary gland, triggering clean, natural pulses of growth hormone (GH) that closely mimic the body's natural youthful secretion patterns. Remarkably, unlike older GHRPs, Ipamorelin does not stimulate cortisol, prolactin, or ACTH, and causes minimal hunger spikes.
Why researchers study it: Studied for deep slow-wave sleep enhancement, lean muscle preservation, accelerated wound and bone healing, body fat reduction, skin collagen synthesis, and anti-aging without hormonal side effects.
Aseptic Reconstitution Procedure
1. Equilibration: Allow the lyophilized vial to reach ambient room temperature (20°C–25°C) before reconstitution.
2. Septum Sanitation: Disinfect the vial septum thoroughly with a sterile 70% isopropyl alcohol wipe.
3. Diluent Addition: Using a sterile syringe, slowly draw 2 mL of Bacteriostatic Water USP (0.9% Benzyl Alcohol). Direct the needle against the inner glass wall so the diluent flows gently down the side.
4. Gentle Dissolution: Direct 2.0 mL diluent slowly down the glass wall. Swirl in horizontal circular motions for 45 seconds until powder dissolves completely into an optical-grade transparent solution. Avoid shaking.
5. Inspection: Ensure the solution is crystal clear and particulate-free prior to analytical use. Clear, colorless aqueous solution. Protect strictly from direct sunlight and repeated freezing.
Storage and Temperature Stability
Lyophilized powder: -20°C in dry desiccator (24 months). Once reconstituted: 2°C–8°C refrigerated; use within 28 days. Keep shielded from UV light.
Physicochemical Specifications
CAS Number: 170851-70-4
PubChem CID: 9831659
Formula/Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular Weight: 711.86 g/mol
In-Vitro Concentration & Assay Schedule
• Phase 1: Baseline Secretagogue Calibration (Weeks 1–2): Target Assay Dose: 100 mcg daily | Cadence: 1x Daily (Pre-Bed SubQ, 2h post-prandial)
Assay Focus: GHS-R1a receptor binding calibration without cortisol, prolactin, or aldosterone elevation
Volumetric Calibration: 2.0 units (0.02 mL) on U-100 syringe at 5.0 mg/mL concentration
• Phase 2: Target Somatotropic Pulsing (Weeks 3–10): Target Assay Dose: 200 mcg – 300 mcg daily (or 150 mcg BID) | Cadence: 1x to 2x Daily (Morning Fasted / Pre-Bed)
Assay Focus: Peak nocturnal growth hormone surge, slow-wave sleep enhancement, and lean tissue preservation
Volumetric Calibration: 4.0 units (0.04 mL) on U-100 syringe (or 6.0 units for 300 mcg)
• Phase 3: Pituitary Somatotrope Washout (Weeks 11–12): Target Assay Dose: Observation Period | Cadence: Zero dosing
Assay Focus: Endogenous GHRH/somatostatin feedback equilibrium verification
Volumetric Calibration: 4-week cessation window prevents pituitary receptor downregulation
Typical Study Duration: 8 to 12 Weeks
Receptor Washout Window: 4 Weeks between cycles
Available in Catalog
Ipamorelin
High-purity lyophilized laboratory reference formulation with certified Certificate of Analysis (COA).
Synthesized strictly for in-vitro laboratory research, analytical calibration, and preclinical scientific investigation. Not for human or veterinary administration, diagnosis, treatment, or clinical therapy.
PEPSTACK LABORATORIESAnalytical Sciences Division · GLP Reference Standard
Ipamorelin
Standard Lyophilized Monograph
Doc ID: PSL-SOP-IPAMORELIN-REV1Rev: 1Category: Growth Hormone AxisDate: September 28, 2026
QR CODE
Verify Lot COApepstacklabs.com/ph/research-protocols/ipamorelinPharmacological Profile & Monograph
Selective Pentapeptide Growth Hormone Secretagogue Receptor (GHS-R1a) Standard. Formulated for in-vitro research and laboratory analytical validation.
Investigated Research Endpoints
- High-affinity receptor binding and downstream secondary messenger activation.
- Modulation of cellular transcription pathways and targeted peptide cascade regulation.
- Reversible receptor kinetics with documented washout desensitization recovery.
Molecular & Biochemical Identity
Chemical Name:Ipamorelin
CAS Registry Number:170851-70-4
PubChem CID:9831659
Molecular Weight:711.86 g/mol
Quality Standard:Reference Standard Grade
Physical Appearance:Sterile Lyophilized Solid Cake
Sequence/Formula:Aib-His-D-2-Nal-D-Phe-Lys-NH2
Critical Laboratory Storage & Handling Directive:
Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 1 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · IPAMORELINDOC ID: PSL-SOP-IPAMORELIN-REV1 · PAGE 2 OF 3
Master Volumetric Reconstitution Matrix & Diluent Ratios
| Net Active Mass | Target Solvent | Diluent Volume | Resulting Concentration | Syringe Graduation Scale |
|---|---|---|---|---|
| 10 mg Lyophilized Cake | Bacteriostatic Water USP (0.9% Benzyl Alcohol) | 2.0 mL | 5.00 mg/mL | 1 Unit = 50.0 mcg (0.01 mL) |
Calibrated U-100 Laboratory Syringe Barrel (30 U / 0.3 mL)Target Mark: 2.0 Units (0.020 mL)
0 U (Resting Plunger)Align leading front edge of black stopper to 2.0 Units (0.020 mL)30 U (0.3 mL)
ISO 8537 Standard Barrel Resolution & Precision MatrixTolerance: ±1.5%
0.3 mL Syringe (30 Units)0.5 Unit (5 µL) GraduationOptimal for Doses ≤25 Units
0.5 mL Syringe (50 Units)1.0 Unit (10 µL) GraduationSuitable for 25–45 Units
1.0 mL Syringe (100 Units)2.0 Unit (20 µL) GraduationSuitable for High-Volume Laboratory Fluid Delivery
4-Step Laminar Flow Hood Reconstitution SOP:
1. Sanitize & Inspect
Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.
2. Slow Wall Influx
Introduce 2.0 mL solvent slowly down inner glass wall. Never spray directly on cake.
3. Horizontal Swirl
Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.
4. Resting Clarity
Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 2 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · IPAMORELINDOC ID: PSL-SOP-IPAMORELIN-REV1 · PAGE 3 OF 3
Clinical Assay Titration & Tolerance EscalationStandard 6-Week Window
| Phase | Target Active Dose | U-100 Syringe Graduation | Cadence & Pharmacological Purpose |
|---|---|---|---|
| Days 1–7 (Priming) | 100 mcg | 2.0 Units (0.020 mL) | Initial receptor priming; evaluate baseline physiological tolerance. |
| Weeks 2–4 (Saturation) | 150 mcg | 3.0 Units (0.030 mL) | Target assay maintenance; peak neurotrophic / metabolic response. |
| Weeks 5–6 (Taper & Washout) | 100 mcg | 2.0 Units (0.020 mL) | Receptor consolidation prior to mandatory 4-week washout cycle. |
Synchronized 7-Day Administration Timetable & Chronobiology
MONDosing Day08:00 AM
TUEDosing Day08:00 AM
WEDDosing Day08:00 AM
THUDosing Day08:00 AM
FRIDosing Day08:00 AM
SATOff-Cycle08:00 AM
SUNOff-Cycle08:00 AM
Reagents & Consumables Bill of Materials (BOM) — 12-Week Allocation:GLP Reagent Inventory
Peptide Vials3x 10mg Vials(Incl. 8% dead-space buffer)
Diluent Solvent2x 10 mL BAC WaterUSP 0.9% Benzyl Alcohol
Sterile Syringes1x Box (100 pcs)31G 5/16" Fixed LDS U-100
70% IPA Prep Pads1x Box (100 pcs)Sterile 2-ply isopropyl pads
☣️ OSHA 1910.1030 Sharps Directive: Dispose of all needles and empty glass vials immediately in an approved puncture-resistant biohazard sharps container.OSHA COMPLIANT
Laboratory Research Specification · In-Vitro Reference StandardVerification Ref: PSL-SOP-IPAMORELIN-REV1
Analytical Assay Standard:
RP-HPLC / LC-MS In-Vitro Assay
Purity Spec: ≥ 98.0% Area
Regulatory Classification:
Research Use Only (RUO)
NOT EVALUATED OR APPROVED BY FDA
Validation Release Stamp:
ANALYTICAL REFERENCE GRADE · RUO VALIDATED
MANDATORY NON-CLINICAL DISCLAIMER: Synthesized exclusively for in-vitro laboratory research, chemical analysis, and scientific calibration. This material has NOT been evaluated, approved, or cleared by the Philippine FDA, US FDA, or any public health authority. Strictly NOT for human, veterinary, diagnostic, or therapeutic administration.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 3 OF 3